Literature DB >> 6660026

Deaths in Swedish hemophiliacs, 1957-1980.

S A Larsson, B Wiechel.   

Abstract

One hundred and eighteen patients with hemophilia A or B died in Sweden between 1957 and 1980. The causes and circumstances of death have been the subject of a retrospective study. The most striking feature was the increase in age at death. In severe hemophilia cases the age increased from 19 in the first half of the period to 50 in the second. In moderate and mild hemophilia cases the increases were similar, although less pronounced. The main cause of death was intracranial hemorrhage, which accounted for one-third of all deaths. In the last 12-year period, however, no patient below the age of 45 had succumbed to this. Age-related causes of death, such as malignancy and ischemic heart disease, had increased, as was to be expected from the increase in the mean and median ages of living hemophiliacs. The proportion of deaths unrelated to hemophilia was 36%. Antibodies were found in 5 (16.7%) of the patients with severe hemophilia A.

Entities:  

Mesh:

Year:  1983        PMID: 6660026     DOI: 10.1111/j.0954-6820.1983.tb08595.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  10 in total

Review 1.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

2.  Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance.

Authors:  Guy Young
Journal:  Blood Adv       Date:  2018-10-23

Review 3.  Progressive change in lymphocyte distribution and degree of hypergammaglobulinemia with age in children with hemophilia.

Authors:  B T Shannon; J Roach; M Cheek-Luten; C Orosz; F B Ruymann
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

4.  The use of blood components in the treatment of congenital coagulation disorders.

Authors:  I M Nilsson; S A Larsson; S E Bergentz
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

5.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

6.  Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review.

Authors:  Tammuella Chrisentery Singleton; Matthew Keane
Journal:  Ochsner J       Date:  2012

7.  Factor VIII and coronary heart disease.

Authors:  F R Rosendaal
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 8.  The legacy of haemophilia: Memories and reflections from three survivors.

Authors:  Albert Farrugia; Cees Smit; Andrea Buzzi
Journal:  Haemophilia       Date:  2022-05-19       Impact factor: 4.263

Review 9.  The management of hemophilia in elderly patients.

Authors:  Massimo Franchini; Annarita Tagliaferri; Pier Mannuccio Mannucci
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  Shortened Lifespan and Lethal Hemorrhage in a Hemophilia A Mouse Model.

Authors:  Janice M Staber; Molly J Pollpeter
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.